CDKN2A and adrenal cortex carcinoma: A similar study by Li et al., showed promoter methylation of p16 (47%), RASSF1A (41%) and DAPK (21%) in a cohort of 60 patients with ACC and indicated that RASSF1A may be linked to metastasis potential in ACC [7], [8].